Exclusive: A longtime VC takes on his own rare disease as Sanofi, Boehringer commit $80M to launch new platform study
Over three decades of investing, Luke Evnin has backed and advised dozens of biotechs developing medicines. Now, the longtime VC is turning his know-how and industry contacts loose on his own rare disease.
The result is a first-of-its-kind Phase IIb trial in scleroderma, with the study recently winning the FDA’s OK to begin, Evnin exclusively told Endpoints News. The study uses a platform design, meaning multiple drugs will be tested against a shared placebo group. Additional treatments can also be added to the trial as it progresses.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.